<DOC>
	<DOC>NCT00111670</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes. The anticipated time on study treatment is &lt; 3 months and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>adult patients 1875 years of age; type 2 diabetes diagnosed &gt;=1 month before screening; no previous treatment, or previous treatment with no more than 2 oral medications. type 1 diabetes; type 2 diabetes treated with insulin or a PPAR gamma agonist during the 3 months before screening; patients who are pregnant, breastfeeding or not using a reliable contraceptive method.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>